Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

IRLAB Therapeutics AB (IRLAB A) NPV A

Sell:48.55 SEK Buy:48.70 SEK Change: 0.35 SEK (0.73%)
Market closed |  Prices as at close on 29 September 2020 | Switch to live prices |
Sell:48.55 SEK
Buy:48.70 SEK
Change: 0.35 SEK (0.73%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 29 September 2020 | Switch to live prices |
Sell:48.55 SEK
Buy:48.70 SEK
Change: 0.35 SEK (0.73%)
Market closed |  Prices as at close on 29 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Contact details

Arvid Wallgrens Backe 20
413 46
+46 (31) 7573800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
2.32 billion SEK
Shares in issue:
48.50 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Anders Vedin
    Independent Chairman of the Board
  • Nicholas Waters
    Chief Executive Officer
  • Carola Lemne
    Independent Vice Chairman of the Board
  • Viktor Siewertz
    Chief Financial Officer
  • Cecilia Tivert Stenberg
    Finance and Human Resources Manager
  • Peder Svensson
    Director of Computational Chemistry & Biology, Chief Information Officer
  • Clas Sonesson
    Chief Scientific Officer
  • Susanna Holm Waters
    Director of Biology & Biostatistics
  • Maria Jalmelid
    Director of Clinical Operations
  • Joakim Tedroff
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.